Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence
Overexpression of C-MYC oncogene in prostate cancer predicts biochemical recurrence
复制标题
DOI：
10.1038/pcan.2010.31
复制
发表时间：
2010-12-01
影响因子：
4.8
通讯作者：
Petrovics, G.
中科院分区：
文献类型：
--
作者：
Hawksworth, D.;Ravindranath, L.;Petrovics, G.
8号染色体的改变，包括携带C-MYC癌基因的8 q24扩增，已被认为是前列腺癌（CaP）进展中最常见的染色体异常之一。然而，CaP中C-MYC改变的频率仍然不确定。最近的一项研究，使用一种新的抗MYC抗体，描述了普遍上调的核C-MYC蛋白表达作为早期致癌性改变的CaP。此外，我们最近报道了ERG对C-MYC表达的调节，以及早期CaP中C-MYC过表达与TMPRSS 2-ERG融合之间的显著相关性。这些新出现的数据表明，增加C-MYC表达可能是一个关键的和早期致癌事件驱动的CaP进展。在这项研究中，我们评估了原发性前列腺肿瘤中C-MYC mRNA的过度表达是否预示着更具侵袭性的肿瘤或疾病进展。我们的方法是定量测定C-MYC mRNA表达水平的激光捕获显微切割肿瘤细胞和匹配的良性上皮细胞在根治性膀胱癌切除术队列与长期随访数据可用。根据我们的研究结果，我们得出结论，原发性前列腺肿瘤中C-MYC表达升高具有生物学相关性，并且可能是未来生化复发的预测因子。前列腺癌和前列腺疾病（2010）13，311-315; doi：10.1038/pcan.2010.31; 2010年9月7日在线发表
Alterations of chromosome 8, including amplification at 8q24 harboring the C-MYC oncogene, have been noted as one of the most common chromosomal abnormalities in prostate cancer (CaP) progression. However, the frequency of C-MYC alterations in CaP has remained uncertain. A recent study, using a new anti-MYC antibody, described prevalent upregulation of nuclear C-MYC protein expression as an early oncogenic alteration in CaP. Further, we have recently reported regulation of C-MYC expression by ERG and a significant correlation between C-MYC overexpression and TMPRSS2-ERG fusion in early stage CaP. These emerging data suggest that increased C-MYC expression may be a critical and early oncogenic event driving CaP progression. In this study, we assessed whether C-MYC mRNA overexpression in primary prostate tumors was predictive of more aggressive tumor or disease progression. Our approach was to quantitatively determine C-MYC mRNA expression levels in laser capture micro-dissected tumor cells and matched benign epithelial cells in a radical prostatectomy cohort with long follow-up data available. On the basis of our results, we conclude that elevated C-MYC expression in primary prostate tumor is biologically relevant and may be a predictor of future biochemical recurrence. Prostate Cancer and Prostatic Diseases (2010) 13, 311-315; doi: 10.1038/pcan.2010.31; published online 7 September 2010